Tuberc Respir Dis.  2015 Jul;78(3):293-296. 10.4046/trd.2015.78.3.293.

Lung Disease Caused by Mycobacterium malmoense in an Immunocompetent Patient

• Jeon MK
• Yoon JA
• Kim J
• Yi S
• Sung H
• Shim TS
• Jo KW

• KMID: 2320660
• DOI: http://doi.org/10.4046/trd.2015.78.3.293

Abstract

Mycobacterium malmoense is a very rare cause of lung disease in South Korea. We reported the first case of lung disease caused by M. malmoense in an immunocompetent patient. The patient was successfully treated with a 14-month course of antibiotics.

Keyword

Mycobacterium Infections; Nontuberculous Mycobacteria; Therapy

MeSH Terms

Anti-Bacterial Agents
Humans
Korea
Lung Diseases*
Mycobacterium Infections
Mycobacterium*
Nontuberculous Mycobacteria
Anti-Bacterial Agents

Figure

• 

  Figure 1 Chest X-ray taken 7 years earlier showing parenchymal destruction, fibrotic lesions, and bullous changes in the right upper lung field caused by a previous episode of pulmonary tuberculosis.

• 

  Figure 2 (A) Chest X-ray showing newly developed infiltrative lesions in the right middle lung area. (B) Low-dose chest computed tomography image showing newly developed segmental centrilobular nodules in the right lung. (C) Low-dose chest computed tomography image showing multifocal patches of consolidation and nodules in the right lung.

• 

  Figure 3 Chest X-ray (A) and low-dose chest computed tomography (B, C) images taken 12 months after the start of treatment showing reduced number and extent of nodules.

Reference

1. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest. 2006; 129:341–348.

2. Park YS, Lee CH, Lee SM, Yang SC, Yoo CG, Kim YW, et al. Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea. Int J Tuberc Lung Dis. 2010; 14:1069–1071.

3. Hoefsloot W, Boeree MJ, van Ingen J, Bendien S, Magis C, de Lange W, et al. The rising incidence and clinical relevance of Mycobacterium malmoense : a review of the literature. Int J Tuberc Lung Dis. 2008; 12:987–993.

4. Hoefsloot W, van Ingen J, de Lange WC, Dekhuijzen PN, Boeree MJ, van Soolingen D. Clinical relevance of Mycobacterium malmoense isolation in The Netherlands. Eur Respir J. 2009; 34:926–931.

5. Buchholz UT, McNeil MM, Keyes LE, Good RC. Mycobacterium malmoense infections in the United States, January 1993 through June 1995. Clin Infect Dis. 1998; 27:551–558.

6. Ryoo SW, Shin S, Shim MS, Park YS, Lew WJ, Park SN, et al. Spread of nontuberculous mycobacteria from 1993 to 2006 in Koreans. J Clin Lab Anal. 2008; 22:415–420.

7. Aksamit TR. Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med. 2002; 23:643–653.

8. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175:367–416.

9. Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax. 2008; 63:627–634.

10. Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment. Eur Respir J. 2003; 21:478–482.

11. Sano C, Tatano Y, Shimizu T, Yamabe S, Sato K, Tomioka H. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium. Int J Antimicrob Agents. 2011; 37:296–301.

12. Fouad M, Gallagher JC. Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis. Ann Pharmacother. 2011; 45:1439–1444.